Day: April 16, 2023

Proposed facilities leverage area’s industrial heritage to recycle waste carbon into sustainable aviation fuel and support UK climate goals GUILDFORD, United Kingdom, April 16, 2023 (GLOBE NEWSWIRE) — LanzaTech UK Ltd, a subsidiary of LanzaTech Global, Inc. (Nasdaq: LNZA) (“LanzaTech” or the “Company”) has announced plans for Wales’ first carbon recycling facilities in and around Port Talbot that would transform emissions into Sustainable Aviation Fuel. The pioneering ‘Project Dragon’ aims to reduce emissions from industry and help facilitate lower emission flying. Building on the area’s industrial strength, the facilities enable Neath Port Talbot to play a leading role in creating carbon reduction industries in South Wales critical to delivering the UK’s net zero economy and tackling the climate emergency. LanzaTech is initially...

Perth, April 17, 2023 (GLOBE NEWSWIRE) — MEYAS SAND GOLD PROJECT UPDATE Perth, Western Australia/April 17, 2023/ Perseus Mining Limited (PRU:ASX/TSX) owns 70% of the Meyas Sand Gold Project (MSGP), in northern Sudan, located approximately 75 kilometres south of the border with Egypt and more than 1,000 kilometres north of Sudan’s capital city, Khartoum. During the weekend, international and domestic media outlets reported on instances of armed conflict between the Sudanese military and an influential militia group, in and around Khartoum. While Perseus does maintain a small office in Khartoum to service the MSGP, its presence in the capital city is minor. Perseus’s staff, both in Khartoum and on site at MSGP, are safe and no damage has been reported to any of its physical assets or infrastructure. Perseus is maintaining a “business...

SAN CARLOS, Calif., April 16, 2023 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it will hold a webcast and conference call tomorrow, April 17, 2023, at 7:30 a.m. Eastern Time to discuss results from the Phase 2 study of VAX-24, the Company’s lead, broad-spectrum 24-valent pneumococcal conjugate vaccine (PCV) candidate, in adults aged 65 and older and full six-month safety data from both adult Phase 2 studies. To participate in the conference call, please dial (800)-267-6316 (domestic) or (203)-518-9783 (international) and refer to conference ID PCVX0417. A live webcast of the conference call will also be available on the investor relations page of the Vaxcyte corporate...

Following the breach in mediation between The Confederation of Norwegian Enterprise (NHO), the Confederation of the Vocational Unions (YS) and the Norwegian Labor Union (LO), employees organized in Industri Energi and FLT at Hydro Karmøy and Hydro Årdal will go on strike from Monday, April 17. The strike will gradually affect the operations at Hydro Karmøy and Hydro Årdal. The impact on operations is regulated by a separate agreement, which states how operations are to be reduced in a responsible manner and how both parties shall contribute. The affected members will go on strike gradually, as ramping down production requires considerable work effort from the operators at the aluminium plants. This process will take several months. Shipping activities will be strictly limited for both Hydro Årdal and Hydro Karmøy for the duration of the...

AFM13 demonstrated robust activity on the primary end point with an objective response rate (ORR) of 32.4% and 10.2% complete response rate (CR) in Intent to Treat (ITT) population Patients with Angioimmunoblastic T cell lymphoma (AITL), one of the most frequent subtypes of peripheral T Cell Lymphoma (PTCL), exhibited the highest ORR (53.3%) and CR (26.7%) Other measures of efficacy included median duration of response (DoR) of 2.3 months, median progression free survival (PFS) of 3.5 months and median overall survival (OS) of 13.8 months in advanced stage relapsed / refractory (r/r) PTCL patients Comparable response rates observed in patients with high and low CD30 expression levels and regardless of prior brentuximab vedotin treatment AFM13 exhibited a tolerable safety profile; most common treatment-emergent adverse events (TEAEs) were...

Abstracts demonstrating XNA technology’s improvements to assay sensitivity across different technology platforms and support for use in companion diagnostics (CDx) assay development Additional abstracts to further support XNA technology’s potential for use in minimal residual disease (MRD) monitoring of residual cancer cellsPLEASANTON, Calif., April 16, 2023 (GLOBE NEWSWIRE) — DiaCarta, Ltd. (“DiaCarta”), a precision molecular diagnostics company, today announced that it will present five data posters at the American Association of Cancer Research (AACR) Annual Meeting 2023, which convenes in Orlando, Florida from April 14-19, 2023. The presentations will focus on how XNA can be used to improve the assay sensitivity of different technology platforms such as Sanger sequencing, qPCR, and Next Generation Sequencing (NGS). DiaCarta’s...

In the first-ever positive Phase III trial in the adjuvant hepatocellular carcinoma (HCC) setting, Tecentriq plus Avastin reduced the risk of disease recurrence by 28%1 Up to 80% of people with this type of HCC experience disease recurrence, at which point they are faced with poorer prognosis and shorter survival2 These data will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2023 and included in the official press programmeBasel, 16 April 2023 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new data from the Phase III IMbrave050 study that show Tecentriq® (atezolizumab) plus Avastin® (bevacizumab) demonstrated a statistically significant improvement in recurrence-free survival (RFS) in people with hepatocellular carcinoma (HCC) at high risk of disease recurrence following liver resection...